RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Il sistema serotoninergico nella fisiopatologia della sindrome dell’intestino irritabile: analisi di meccanismi molecolari e farmacologici finalizzata alla ricerca di nuove opzioni terapeutiche
• 2 - FATTORI PREDISPONENTI L'INFIAMMAZIONE CRONICA DELL'INTESTINO:BATTERI,VIRUS,PERMEABILITA' INTESTINALE E PREDISPOSIZIONE GENETICA
• 3 - IMMUNITA' INNATA E MALATTIA CELIACA
• 4 - Determinanti genetici e molecolari del ruolo della COX-2 nell'aterotrombosi.
• 5 - MALATTIE INFIAMMATORIE INTESTINALI DEL BAMBINO: STUDIO DELLA ESPRESSIONE DI GENI IN RAPPORTO ALLA IMMUNITA' INNATA, ALLA IMMUNITA' RITARDATA E ALLA RISPOSTA ALLA TERAPIA IMMUNOMODULANTE.
• 6 - Effetti clinici e molecolari dell'eccesso di glucocorticoidi
• 7 - MECCANISMI MOLECOLARI DELLE EPILESSIE PARZIALI FARMACORESISTENTI
• 8 - MECCANISMI MUCOSALI DI DANNO E RIPARAZIONE NELLE MALATTIE INFIAMMATORIE CRONICHE INTESTINALI (MICI)
• 9 - Meccanismi di adattamento al danno neuromuscolare nell’apparato gastroenterico: ruolo delle vie glutammatergiche enteriche
• 10 - Nuove prospettive nella fibrillazione atriale: dalla ricerca di base all'approccio terapeutico farmacologico e chirurgico.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • FARMACOLOGIA

Classificazione brevettuale

• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Lombardia

Bibliografia

1) Gunn M.C., Cavin A.A., Mansfield J.C. Management of irritable bowel syndrome. Postgrad Med J 2003; 79: 154-158.
2) Serra J., Aspiroz F., Malagelada J.R. Intestinal gas dynamics and tolerance in humans. Gastroenterology 1998; 115: 542-550.
3) Mayer E.A., Gebhart G.F. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271-293.
4) De Ponti F., Malagelada J.R. Functional gut disorders: from motility to sensitivity disorders: a review of current and investigational drugs for their management. Pharmacol Ther 1998; 80: 49-88.
5) Gwee K.A., Leong Y.L, Graham C. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-406.
6) Gorelick A.B., Koshy S.S., Hooper F.G. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998; 275: G460-G466.
7) Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001;120: 652-668.
8) Barbara G., De Giorgio R., Stanghellini V., Cremon C., Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002; 51 (Suppl 1): i41-i44.
9) De Giorgio R., Barbara G., Blennerhassett P., Wang L., Stanghellini V., Corinaldesi R., Collins S.M., Tougas G. Intestinal inflammation and activation of sensory nerve pathways: a functional and morphological study in the nematode infected rat. Gut 2001; 49: 822-827.
10) Giaroni C., De Ponti F., Cosentino M., Lecchini S., Frigo G. Plasticity in the enteric nervous system. Gastroenterology 1999; 117: 1438-1458.
11) Bueno L., Fioramonti J., Delvaux M., Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112: 1714-1743.
12) De Ponti F., Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001; 61: 317-332.
13) Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Collins S.M., Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
14) Vergnolle N., Ferazzini M., D’Andrea M.R., Buddenkotte J., Steinhoff M. Proteinase-activated receptors: novel signals for peripheral nerves. Trends Neurosci 2003; 26: 496-500.
15) Gershon M.D. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disorders 2003; 3 (Suppl.2): S25-S34.
16) Gershon M.D. Serotonin: its role and receptors in enteric neurotransmission. In: Scharcz R, Young SN, Brown RR eds. Kynurenine and serotonin pathways: progress in tryptophan research, vol 294. Baltimore Maryland: Plenum Publishing,1991: pag. 221-230.
17) Bearcroft C.P., Perret D., Farthing M.J.G. Postprandial plasma 5-hydroxytryptamine in diarrhoea-predominant irritable bowel syndrome: a pilot study. Gut 1998; 42:.42-46.
18) Bellini M., Rappelli L., Blandizzi C., Costa F., Stasi C., Colucci R., Giannaccini G., Marazziti D., Betti L., Baroni S., Mumolo M.G., Marchi S., Del Tacca M. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel sindrome both before and after treatment with alosetron. Am J Gastroenterol 2003; 98: 2704-2709.
19) Kim D.Y., Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95: 2698-2709.
20) Lesch K.P., Wolozin B.L., Murphy D.L., Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993; 60: 2319-2322.
21) Chen J.-X., Pan H., Rothman T.P., Wade P.R., Gershon M.D. Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am J Physiol 1998; 275: G433-438.
22) Chen J.J., Li Z., Pan H. Murphy D.L., Tamir H., Koepsell H., Gershon M.D. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001; 21: 6348-6361.
23) Camilleri M., Atanasova E., Carlson P.J., Ahmad U., Kim H.J., Viramontes B.E., McKinzie S., Urrutia R. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant IBS. Gastroenterology 2002; 123: 423-432.
24) Lesch K.P. Variation of serotonergic gene expression: neurodevelopment and the complexity of response to psychopharmacologic drugs. J Psychopharmacol 2001; 11: 457-474.
25) Pata C., Erdal M.E., Derici E., Yazar A., Kanik A., Ulu O. Serotonin transporter gene polymorphism in IBS, Am J Gastroenterol 2002; 97: 1780-1784.
26) Hansen M.B., Dresner L.S., Wait R.B. Profile of neurohumoral agents on mesenteric and intestinal blood flow in health and disease. Physiol Res 1998; 47: 307-327.
27) Carden D.L., Granger D.N. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000; 190: 255-266.
28) Squadrito F., Altavilla D., Canale P., Ioculano M., Campo G.M., Ammendolia L., Ferlito M., Zingarelli B., Squadrito G., Saitta A. Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock. Br J Pharmacol 1994; 113: 1153-1158.
29) Cuzzocrea S., Zingarelli B., Costantino G., Szabo A., Salzman A.L., Caputi A.P., Szabo C. Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. Br J Pharmacol 1997; 121: 1065-1074.
30) Ballabeni V., Barocelli E., Bertoni S., Impicciatore M. Alterations of intestinal motor responsiveness in a model of mild mesenteric ischemia/reperfusion in rats. Life Sci 2002; 71: 2025-2035.
31) Calcina F., Barocelli E., Bertoni S., Impicciatore M., Sternini C. Glutamate-receptor activation mediates the effects of ischemia/reperfusion on gastrointestinal transit and neuronal phenotypes in the rat myenteric plexus. Proceeding of XII Biennal meeting of American Motility Society 2002.
32) Friedel D., Thomas R., Fisher R.S. Ischemic colitis during treatment with alosetron. Gastroenterology 2001; 120: 557-560.
33) Gershon M.D. Plasticity in serotonin control mechanisms in the gut. Curr Opin Pharmacol 2003; 3: 600-607.
34) Liu J.J., Brandhagen D.J., Ardolf J.C. Sumatriptan-associated mesenteric ischemia. Ann Intern Med 2000; 132: 597.
35) Teramoto Y., Urano T., Nagai N., Takada Y., Ikeda K., Takada A. Plasma levels of 5-HT and 5-HIAA increased after intestinal ischemia/reperfusion in rats. Jpn J Physiol 1998; 48: 333-339.
36) Nakamura N., Hamada N., Murata R., Kobayashi A., Ishizaki N., Taira A., Sakata R. Contribution of serotonin to liver injury following canine small-intestinal ischemia and reperfusion. J Surg Res 2000; 99: 17-24.
37) Yamada T., Inui A., Hayashi N., Fujimura M., Fujimiya M. Serotonin stimulates endotoxin translocation via 5-HT3 receptors in the rat ileum. Am J Physiol 2003; 284: G782-G788.
38) Hohlfeld T., Braun M., Strobach H., Schror K. Protection of reperfused ischemic pig myocardium by nexopamil, a new combined Ca2+ and serotonin antagonist. J Cardiovasc Pharmacol 1994; 23: 922-931.
39) Choudhury N.A., Malyszko J., Ahmed M.H., Pietraszek M.H., Nakamura S., Nakai K., Rashid M.A., Takada A., Baba S. Plasma serotonin and platelet aggregation during ischemia-reperfusion in dogs: effect of dipyridamole and coenzyme Q10. Haemostasis 1996; 26:38-44.
40) Caty M.G., Guice K.S., Oldham K.T., Remick D.G., Kunkel S. Evidence for tumor necrosis factor-induced pulmonary microvascular injury after intestinal ischemia-reperfusion injury. Ann Surg 1990; 212: 694-700.
41) Cloez-Tayarani I., Petit-Bertron A.F., Venters H.D., Cavaillon J.M. Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine2A receptors. Int Immunol 2003; 15: 233-240.

Parole Chiave

SINDROME DELL'INTESTINO IRRITABILE; SISTEMA NERVOSO ENTERICO; SEROTONINA; INFIAMMAZIONE INTESTINALE; ISCHEMIA INTESTINALE